Myasthenia Gravis Induced by Nivolumab: A Case Report

Nivolumab is a programmed cell death receptor (PD-1) inhibitor therapy for aggressive cancers; however, it poses a risk of immune-related adverse side effects. We present a 73-year-old male with renal cell carcinoma who developed myasthenia gravis (MG) after being treated with nivolumab, proven by a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Jeet J, Maloney, Eamon, Srinivasan, Sachin, Seitz, Patrick, Cannon, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690486/
https://www.ncbi.nlm.nih.gov/pubmed/29159009
http://dx.doi.org/10.7759/cureus.1702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690486/
https://www.ncbi.nlm.nih.gov/pubmed/29159009
http://dx.doi.org/10.7759/cureus.1702

Ejemplares similares